Mostrar el registro sencillo del ítem

Artículo

dc.creatorDelgado, J. F.es
dc.creatorOliva, J.es
dc.creatorGonzález-Franco, A.es
dc.creatorCepeda, J. M.es
dc.creatorGarcía García, José Ángeles
dc.creatorGonzález-Domínguez, A.es
dc.creatorGarcía-Casanovas, A.es
dc.creatorJiménez Merino, S.es
dc.creatorComín-Colet, J.es
dc.date.accessioned2023-07-20T09:51:18Z
dc.date.available2023-07-20T09:51:18Z
dc.date.issued2020
dc.identifier.citationDelgado, J.F., Oliva, J., González-Franco, A., Cepeda, J.M., García García, J.Á., González-Domínguez, A.,...,Comín-Colet, J. (2020). Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain. Journal of Medical Economics (JME), 23 (12), 1418-1424. https://doi.org/10.1080/13696998.2020.1838872.
dc.identifier.issn1369-6998es
dc.identifier.issn1941-837Xes
dc.identifier.urihttps://hdl.handle.net/11441/148120
dc.description.abstractObjective The treatment of iron deficiency (ID) with ferric carboxymaltose (FCM) improves the functional class and quality of life of chronic heart failure (CHF) patients with reduced left ventricular ejection fraction (LVEF), and reduces the rate of hospitalization due to worsening CHF. This study aims to evaluate the budget impact for the Spanish National Health System (SNHS) of treating ID in reduced LVEF CHF with FCM compared to non-iron treatment. Methods We simulated a hypothetical cohort of 1000 CHF patients with ID and reduced LVEF based on the Spanish population characteristics. A decision-analytic model was also built using the data from the largest FCM clinical trial (CONFIRM-HF) that lasted for a year. We considered the use of healthcare resources from a national prospective study. A deterministic sensitivity analysis was carried out varying the corresponding baseline data by ±25%. Results The cost of treating the simulated population with FCM was €2,570,914, while that of the non‐iron treatment was €3,105,711, which corresponds to a cost saving of €534,797 per 1,000 patients in one year. Cost savings were mainly due to a decrease in the number of hospitalizations. All sensitivity analysis showed cost savings for the SNHS. Conclusions FCM results in an annual cost saving of €534.80 per patient, and would thus be expected to reduce the economic burden of CHF in Spain.es
dc.formatapplication/pdfes
dc.format.extent7 p.es
dc.language.isoenges
dc.publisherTaylor and Francis Groupes
dc.relation.ispartofJournal of Medical Economics (JME), 23 (12), 1418-1424.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectBudget impactes
dc.subjectH51es
dc.subjectChronic heart failurees
dc.subjectFerric carboxymaltosees
dc.subjectHeart failurees
dc.subjectIron deficiencyes
dc.titleBudget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spaines
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.relation.publisherversionhttps://www.tandfonline.com/doi/full/10.1080/13696998.2020.1838872es
dc.identifier.doi10.1080/13696998.2020.1838872es
dc.journaltitleJournal of Medical Economics (JME)es
dc.publication.volumen23es
dc.publication.issue12es
dc.publication.initialPage1418es
dc.publication.endPage1424es
dc.contributor.funderVifor Pharma, Spaines

FicherosTamañoFormatoVerDescripción
Budget impact of ferric carbox ...2.423MbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional